Hemophilia A
14 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AAV2/8-HLP-FVIII-V3 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ANB-010, dose 1 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ANB-010, dose 2 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ANB-010, dose 3 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| efanesoctocog alfa (BIVV001) for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fidanacogene Elaparvovec for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Fitusiran for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Marstacimab for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPK-8011QQ for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SR604 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zemocimig for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |